162 related articles for article (PubMed ID: 22049355)
1. Bromocriptine: its place in type 2 diabetes Tx.
Sando KR; Taylor J
J Fam Pract; 2011 Nov; 60(11):E1-5. PubMed ID: 22049355
[TBL] [Abstract][Full Text] [Related]
2. Evidence-based practice use of quick-release bromocriptine across the natural history of type 2 diabetes mellitus.
Schwartz SS; Zangeneh F
Postgrad Med; 2016 Nov; 128(8):828-838. PubMed ID: 27458683
[TBL] [Abstract][Full Text] [Related]
3. Rapid and dramatic glucose-lowering effect of bromocriptine in an inadequately controlled type 2 diabetes patient with prolactinoma.
Igata M; Yagi Y; Hanatani S; Sakaguchi M; Ishii N; Yoshinaga K; Kawashima J; Motoshima H; Araki E
J Diabetes Investig; 2021 Apr; 12(4):668-671. PubMed ID: 32706496
[TBL] [Abstract][Full Text] [Related]
4. Bromocriptine mesylate (Cycloset) for type 2 diabetes mellitus.
Weiland CM; Hilaire ML
Am Fam Physician; 2013 May; 87(10):718-20. PubMed ID: 23939451
[No Abstract] [Full Text] [Related]
5. Bromocriptine--unique formulation of a dopamine agonist for the treatment of type 2 diabetes.
Scranton R; Cincotta A
Expert Opin Pharmacother; 2010 Feb; 11(2):269-79. PubMed ID: 20030567
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and Safety of Bromocriptine-QR as an Adjunctive Therapy on Glycemic Control in Subjects with Uncontrolled Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis.
Yanto TA; Budiputri CL; Muljono MP; Chandra S
J ASEAN Fed Endocr Soc; 2024; 39(1):95-105. PubMed ID: 38863918
[TBL] [Abstract][Full Text] [Related]
7. A review of dopamine agonist therapy in type 2 diabetes and effects on cardio-metabolic parameters.
Lamos EM; Levitt DL; Munir KM
Prim Care Diabetes; 2016 Feb; 10(1):60-5. PubMed ID: 26670921
[TBL] [Abstract][Full Text] [Related]
8. Does bromocriptine improve glycemic control of obese type-2 diabetics?
Aminorroaya A; Janghorbani M; Ramezani M; Haghighi S; Amini M
Horm Res; 2004; 62(2):55-9. PubMed ID: 15205563
[TBL] [Abstract][Full Text] [Related]
9. Select medications that unexpectedly lower HbA1c levels.
Tillman F; Kim J
J Clin Pharm Ther; 2018 Aug; 43(4):587-590. PubMed ID: 29671894
[TBL] [Abstract][Full Text] [Related]
10. Bromocriptine mesylate for glycemic management in type 2 diabetes mellitus.
Kerr JL; Timpe EM; Petkewicz KA
Ann Pharmacother; 2010 Nov; 44(11):1777-85. PubMed ID: 20978217
[TBL] [Abstract][Full Text] [Related]
11. Dopamine: the forgotten felon in type 2 diabetes.
Kalra S; Kalra B; Agrawal N; Kumar S
Recent Pat Endocr Metab Immune Drug Discov; 2011 Jan; 5(1):61-5. PubMed ID: 22074579
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic potential of dopamine agonists in the treatment of type 2 diabetes mellitus.
Kabir MT; Ferdous Mitu J; Akter R; Akhtar MF; Saleem A; Al-Harrasi A; Bhatia S; Rahman MS; Damiri F; Berrada M; Rahman MH
Environ Sci Pollut Res Int; 2022 Jul; 29(31):46385-46404. PubMed ID: 35486279
[TBL] [Abstract][Full Text] [Related]
13. Late phase completed clinical trials investigating bromocriptine mesylate quick release as treatment of type 2 diabetes mellitus.
Siamashvili M; Davis S
Expert Opin Pharmacother; 2021 Feb; 22(2):241-247. PubMed ID: 33030357
[TBL] [Abstract][Full Text] [Related]
14. The Effect of Atorvastatin on Cardiometabolic Risk Factors in Bromocriptine-Treated Premenopausal Women with Isolated Hypercholesterolemia.
Krysiak R; Gilowski W; Szkrobka W; Okopien B
Cardiovasc Ther; 2015 Oct; 33(5):282-7. PubMed ID: 26146893
[TBL] [Abstract][Full Text] [Related]
15. Quick-release bromocriptine for treatment of type 2 diabetes.
Mikhail N
Curr Drug Deliv; 2011 Sep; 8(5):511-6. PubMed ID: 21696353
[TBL] [Abstract][Full Text] [Related]
16. Impact of Bromocriptine-QR Therapy on Glycemic Control and Daily Insulin Requirement in Type 2 Diabetes Mellitus Subjects Whose Dysglycemia Is Poorly Controlled on High-Dose Insulin: A Pilot Study.
Roe ED; Chamarthi B; Raskin P
J Diabetes Res; 2015; 2015():834903. PubMed ID: 26060825
[TBL] [Abstract][Full Text] [Related]
17. Timed Bromocriptine-QR Therapy Reduces Progression of Cardiovascular Disease and Dysglycemia in Subjects with Well-Controlled Type 2 Diabetes Mellitus.
Chamarthi B; Gaziano JM; Blonde L; Vinik A; Scranton RE; Ezrokhi M; Rutty D; Cincotta AH
J Diabetes Res; 2015; 2015():157698. PubMed ID: 26060823
[TBL] [Abstract][Full Text] [Related]
18. New insights into the older hypoglycemic agents in type 2 diabetes therapy.
Cao M; Bloomgarden Z
J Diabetes; 2020 Nov; 12(11):844-847. PubMed ID: 32767624
[No Abstract] [Full Text] [Related]
19. Novel therapies for the management of type 2 diabetes mellitus: part 1. pramlintide and bromocriptine-QR.
Grunberger G
J Diabetes; 2013 Jun; 5(2):110-7. PubMed ID: 23452312
[TBL] [Abstract][Full Text] [Related]
20. Clinical inquiries. How beneficial are thiazolidinediones for diabetes mellitus?
Culhane NS; Graves R
J Fam Pract; 2002 May; 51(5):424. PubMed ID: 12019048
[No Abstract] [Full Text] [Related]
[Next] [New Search]
